Concord Biotech Q2 FY27: PAT ₹58 & Rev ₹257 Cr

Metric	Value
Revenue	₹257 Cr
Net Profit (PAT)	₹58

📢 Key Event
Concord Biotech reported Q1 FY27 results with 26% YoY revenue growth to INR 257 crores.

🔄 What Changed
Revenue grew 26% YoY to INR 257 crores; EBITDA margin target raised to 40% by FY28; CDMO revenue contribution expected to grow from 1-2% to double digits; capacity utilization in injectables facility increased to 80% in Unit 1.

🔮 What's Next
Targeting INR 3,000 crores revenue by FY28; EBITDA margin target of 40% by FY28; CDMO revenue to grow from 1-2% to double digits; capacity utilization to reach 80-85% to trigger brownfield expansion at Limbasi; commercial launch of fusidic acid and mycophenolate mofetil underway; export approvals for injectables pending 12-15 months.

💡 Investor Takeaway
The company is scaling manufacturing and CDMO capabilities to drive higher-margin growth, targeting significant revenue expansion from existing infrastructure while maintaining a strong cash position and zero debt.

Concord Biotech reported Q1 FY27 revenue of INR 257 crores, up 26% YoY, driven by 46% export growth and new product approvals. Gross margins stood at 78.9%, EBITDA at 32%, with INR 58 crores PAT. The company holds INR 442 crores cash and zero debt, targeting INR 3,000 crores revenue by FY28 from existing infrastructure. Key launches include fusidic acid and mycophenolate mofetil, with injectables facility scaling toward 80-85% utilization. CDMO opportunities are nascent but expected to grow, supported by capacity expansion and renewable energy initiatives.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CONCORDBIO ✨ Ask AI About This

About Concord Biotech Limited (CONCORDBIO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹15,212.77 Cr P/E: 55.7 ROE: 13.5% ROCE: 18.1% Div Yield: 0.52%

View full CONCORDBIO stock details →

📡 Get AI alerts when CONCORDBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CONCORDBIO — Free

💡 Ask AI about this filing

"What is the timeline for achieving the 40% EBITDA margin target?" "When will the injectables facility reach 80-85% utilization to trigger expansion?" "What is the expected revenue contribution from CDMO services by FY28?"

Ask AI Free →

📊 More CONCORDBIO filings

See all CONCORDBIO filings →

🔥 Also filed on 7 August 2026

OLAELEC Ola Electric Mobility Limited Financial Results NCC NCC Limited Financial Results GRWRHITECH Garware Hi-Tech Films Limited Financial Results ARVSMART Arvind SmartSpaces Limited Financial Results BEML BEML Limited Financial Results RUSTOMJEE Keystone Realtors Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CONCORDBIO files new disclosures

Track CONCORDBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CONCORDBIO — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd